Point72 (DIFC)’s Outlook Therapeutics OTLK Stock Holding History

Point72 (DIFC)’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-383	Closed	-$613	–	1697
2025 Q2	$613	Buy	+383	New	+$611	﹤0.01%	1454

Other funds holding OTLK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 (DIFC)'s OTLK Position: Q3 2025 in Review

Point72 (DIFC) sold out of Outlook Therapeutics (OTLK) in Q3 2025, closing a stake of 383 shares — an estimated $613 sold.

Point72 (DIFC) first reported a position in OTLK in Q2 2025 and held it in 1 quarter. The position peaked at $613 in Q2 2025. 54 funds tracked by Wall St. Rank hold OTLK as of Q3 2025.

Point72 (DIFC) reported no remaining Outlook Therapeutics position as of Q3 2025 after selling out during the quarter.
Point72 (DIFC) sold 383 Outlook Therapeutics shares in Q3 2025, an estimated $613.
Point72 (DIFC) first reported a position in Outlook Therapeutics in Q2 2025 and held it in 1 quarter.
Point72 (DIFC)'s Outlook Therapeutics position peaked at $613 in Q2 2025.
54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.